600638-84-4Relevant articles and documents
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors
Anderson, Malcolm,Andrews, David M.,Barker, Andy J.,Brassington, Claire A.,Breed, Jason,Byth, Kate F.,Culshaw, Janet D.,Finlay, M. Raymond V.,Fisher, Eric,McMiken, Helen H.J.,Green, Clive P.,Heaton, Dave W.,Nash, Ian A.,Newcombe, Nicholas J.,Oakes, Sandra E.,Pauptit, Richard A.,Roberts, Andrew,Stanway, Judith J.,Thomas, Andrew P.,Tucker, Julie A.,Walker, Mike,Weir, Hazel M.
scheme or table, p. 5487 - 5492 (2009/05/30)
An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed. Protein inhibitor structure determination has provided an understanding of the emerging structure activity trends for the imidazole series. The introduction of a methyl sulfone at the aniline terminus led to a more orally bioavailable CDK inhibitor that was progressed into clinical development.
